Plain-English translation of NCT05374278 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new radioactive tracer called [18F]RP-115 that lights up specific changes in the brain during PET scans. The goal is to see if this imaging tool can detect early signs of dementia—specifically Alzheimer's disease and frontotemporal dementia—before symptoms become severe. The medication works by highlighting a protein in the brain that tends to decrease when dementia develops, potentially allowing doctors to diagnose these conditions much earlier.
Right now, doctors struggle to diagnose Alzheimer's and frontotemporal dementia early because there is no reliable single test—they have to rely on memory tests and patient history, which often leads to delayed or missed diagnoses. This medication could revolutionize how we detect these diseases early, improve patient outcomes, and help develop better treatments.
You likely qualify if…
You likely don't qualify if…
Participants in this study will receive an injection of the new radioactive tracer and then undergo brain imaging scans (PET and MRI) to see how the medication lights up different areas of the brain. Healthy volunteers will help establish that the medication is safe, while patients with dementia diagnoses will be compared to age-matched healthy controls to see if the tracer can detect differences in brain activity. The study involves at least one imaging visit, and participants must have had recent cognitive testing within the past six months if they have dementia.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States